Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dex BTC restrictions?

This article was originally published in The Tan Sheet

Executive Summary

The Army & Air Force Exchange Service has adopted a voluntary plan prohibiting the sale of dextromethorphan (DXM) products to those under the age of 18, the AAFES announces Feb. 9. The policy, enacted Jan. 24, is designed to prevent teenagers from using the drug for recreational purposes. Military members can still purchase DXM products such as Wyeth's Robitussin andAdams' Mucinex over-the-counter at Base Exchange/Post Exchange stores, but will have to show proof of age at check-out. Walgreens enacted a similar nationwide policy in July 2005 in response to an FDA "Talk Paper" highlighting DXM abuse (1"The Tan Sheet" July 4, 2005 p. 12)...

You may also be interested in...



Walgreens Sets Dextromethorphan Age Limit Policy To Curb Abuse

Retailers are working to stay ahead of state legislators looking to place restrictions on products containing the cough suppressant ingredient dextromethorphan (DXM)

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel